Trial Profile
Randomized, Double-blind, Placebo-controlled Phase III Study of APD421 (Amisulpride for IV Injection) as Prophylaxis Against Post-operative Nausea and Vomiting
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 Feb 2019
Price :
$35
*
At a glance
- Drugs Amisulpride (Primary)
- Indications Postoperative nausea and vomiting
- Focus Registrational; Therapeutic Use
- Sponsors Acacia Pharma
- 07 Oct 2014 Primary endpoint (significantly lower proportion of amisulpride vs placebo recipients with no PONV in postoperative 24h) has been met, according to an Acacia media release.
- 07 Oct 2014 Top-line results reported in an Acacia media release.
- 26 Nov 2013 New trial record